These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants. Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009 [TBL] [Abstract][Full Text] [Related]
67. A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias. Said HM; Kaya D; Yavuz I; Dost FS; Altun ZS; Isik AT Clin Interv Aging; 2022; 17():467-477. PubMed ID: 35431542 [TBL] [Abstract][Full Text] [Related]
68. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257 [TBL] [Abstract][Full Text] [Related]
69. Analysis of combined CSF biomarkers in AD diagnosis. De Riva V; Galloni E; Marcon M; Di Dionisio L; Deluca C; Meligrana L; Bolner A; Perini F Clin Lab; 2014; 60(4):629-34. PubMed ID: 24779297 [TBL] [Abstract][Full Text] [Related]
70. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Riemenschneider M; Lautenschlager N; Wagenpfeil S; Diehl J; Drzezga A; Kurz A Arch Neurol; 2002 Nov; 59(11):1729-34. PubMed ID: 12433260 [TBL] [Abstract][Full Text] [Related]
71. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Hampel H; Goernitz A; Buerger K Brain Res Bull; 2003 Aug; 61(3):243-53. PubMed ID: 12909294 [TBL] [Abstract][Full Text] [Related]
72. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663 [TBL] [Abstract][Full Text] [Related]
73. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test. Kang K; Ko PW; Jin M; Suk K; Lee HW J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892 [TBL] [Abstract][Full Text] [Related]
74. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Amft M; Ortner M; Eichenlaub U; Goldhardt O; Diehl-Schmid J; Hedderich DM; Yakushev I; Grimmer T Alzheimers Res Ther; 2022 Apr; 14(1):60. PubMed ID: 35473631 [TBL] [Abstract][Full Text] [Related]
75. Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. Berge G; Lauridsen C; Sando SB; Holder DJ; Møller I; Aasly JO; Bråthen G; Savage MJ; White LR J Alzheimers Dis; 2016; 49(2):493-502. PubMed ID: 26484901 [TBL] [Abstract][Full Text] [Related]
76. Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Maxwell TJ; Corcoran C; Del-Aguila JL; Budde JP; Deming Y; Cruchaga C; Goate AM; Kauwe JSK; Alzheimers Res Ther; 2018 Aug; 10(1):86. PubMed ID: 30153862 [TBL] [Abstract][Full Text] [Related]
77. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM; Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642 [TBL] [Abstract][Full Text] [Related]
78. Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Adamczuk K; Schaeverbeke J; Vanderstichele HM; Lilja J; Nelissen N; Van Laere K; Dupont P; Hilven K; Poesen K; Vandenberghe R Alzheimers Res Ther; 2015 Dec; 7(1):75. PubMed ID: 26677842 [TBL] [Abstract][Full Text] [Related]
79. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906 [TBL] [Abstract][Full Text] [Related]
80. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R; Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]